NASDAQ:EDAP

Edap Tms Competitors

$9.08
+0.03 (+0.33 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.78
Now: $9.08
$9.24
50-Day Range
$7.27
MA: $8.48
$9.68
52-Week Range
$2.00
Now: $9.08
$10.68
Volume81,486 shs
Average Volume285,680 shs
Market Capitalization$264.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92

Competitors

Edap Tms (NASDAQ:EDAP) Vs. NTUS, AXGN, TMDX, VRAY, CUTR, and ZYXI

Should you be buying EDAP stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Edap Tms, including Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), ViewRay (VRAY), Cutera (CUTR), and Zynex (ZYXI).

Natus Medical (NASDAQ:NTUS) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares Natus Medical and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$495.52 million1.93$-15,670,000.00$1.2422.76
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Natus Medical and Edap Tms, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natus Medical01002.00
Edap Tms00303.00

Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than Natus Medical.

Volatility and Risk

Natus Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natus Medical-4.33%3.87%2.50%
Edap Tms-4.03%-11.54%-5.78%

Insider & Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AxoGen (NASDAQ:AXGN) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares AxoGen and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.20$-29,140,000.00($0.68)-27.72
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AxoGen and Edap Tms, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
Edap Tms00303.00

AxoGen currently has a consensus target price of $23.75, indicating a potential upside of 25.99%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than AxoGen.

Volatility and Risk

AxoGen has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Profitability

This table compares AxoGen and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
Edap Tms-4.03%-11.54%-5.78%

Insider & Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Edap Tms beats AxoGen on 8 of the 13 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

76.7% of TransMedics Group shares are owned by institutional investors. 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

TransMedics Group has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares TransMedics Group and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$23.60 million31.35$-33,550,000.00($2.36)-11.45
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TransMedics Group and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TransMedics Group-131.35%-38.95%-24.10%
Edap Tms-4.03%-11.54%-5.78%

Analyst Ratings

This is a breakdown of current recommendations for TransMedics Group and Edap Tms, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TransMedics Group02302.60
Edap Tms00303.00

TransMedics Group presently has a consensus target price of $44.20, indicating a potential upside of 63.52%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Edap Tms.

Summary

Edap Tms beats TransMedics Group on 7 of the 13 factors compared between the two stocks.

ViewRay (NASDAQ:VRAY) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

83.0% of ViewRay shares are owned by institutional investors. 15.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

ViewRay has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares ViewRay and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$87.78 million8.02$-120,200,000.00($1.18)-3.71
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has lower revenue, but higher earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ViewRay and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ViewRay-166.74%-63.41%-36.34%
Edap Tms-4.03%-11.54%-5.78%

Analyst Ratings

This is a breakdown of current recommendations for ViewRay and Edap Tms, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ViewRay11502.57
Edap Tms00303.00

ViewRay presently has a consensus target price of $4.50, indicating a potential upside of 2.74%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than ViewRay.

Summary

Edap Tms beats ViewRay on 8 of the 14 factors compared between the two stocks.

Cutera (NASDAQ:CUTR) and Edap Tms (NASDAQ:EDAP) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

87.8% of Cutera shares are owned by institutional investors. 2.3% of Cutera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Cutera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cutera and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cutera$181.71 million2.95$-12,350,000.00($0.88)-34.28
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has lower revenue, but higher earnings than Cutera. Cutera is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cutera and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cutera-18.83%-61.21%-25.31%
Edap Tms-4.03%-11.54%-5.78%

Analyst Ratings

This is a breakdown of current recommendations for Cutera and Edap Tms, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cutera01302.75
Edap Tms00303.00

Cutera presently has a consensus target price of $30.6667, indicating a potential upside of 1.65%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than Cutera.

Summary

Edap Tms beats Cutera on 9 of the 13 factors compared between the two stocks.

Zynex (NASDAQ:ZYXI) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Zynex and Edap Tms, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zynex02202.50
Edap Tms00303.00

Zynex presently has a consensus target price of $21.6250, indicating a potential upside of 40.79%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Zynex's higher probable upside, analysts plainly believe Zynex is more favorable than Edap Tms.

Risk & Volatility

Zynex has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares Zynex and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynex$45.47 million11.77$9.49 million$0.2854.86
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Zynex has higher earnings, but lower revenue than Edap Tms. Zynex is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

29.6% of Zynex shares are owned by institutional investors. 50.5% of Zynex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Zynex and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zynex18.08%50.67%35.56%
Edap Tms-4.03%-11.54%-5.78%

Summary

Zynex beats Edap Tms on 10 of the 14 factors compared between the two stocks.


Edap Tms Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NTUS
Natus Medical
1.1$28.22+0.9%$955.92 million$495.52 million-51.31
AxoGen logo
AXGN
AxoGen
1.7$18.85+3.4%$768.55 million$106.71 million-29.92
TransMedics Group logo
TMDX
TransMedics Group
1.6$27.03+2.1%$739.81 million$23.60 million-19.31Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.3$4.38+1.4%$704.31 million$87.78 million-4.92
Cutera logo
CUTR
Cutera
1.3$30.17+1.8%$536.51 million$181.71 million-16.67News Coverage
Zynex logo
ZYXI
Zynex
1.8$15.36+0.2%$535.37 million$45.47 million46.55
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.36+11.4%$171.12 million$3.38 million-3.85Decrease in Short Interest
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.88+4.4%$123.35 millionN/A0.00
FONR
FONAR
1.1$18.32+2.9%$120.07 million$85.69 million17.28News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.71+3.0%$119.67 million$43.45 million-14.02
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.15+2.6%$91.68 millionN/A-1.51Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.18+1.8%$90.69 million$10,000.00-1.18Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.79+1.7%$86.77 million$2.39 million-2.27Decrease in Short Interest
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$16.90+1.3%$39.06 million$1.50 million-0.97Analyst Upgrade
Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.37+0.4%$32.42 million$5.51 million-0.11Analyst Downgrade
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63+5.7%$27.20 million$6.57 million-0.01
STRR
Star Equity
0.1$2.80+5.4%$13.78 million$114.18 million-0.89
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.